Harwell Science and Innovation Campus, a 50:50 Joint Venture between private sector investor Brookfield (50%) and the Science and Technology Facilities Council, the UK Atomic Energy Authority (50%) has announced the next phase of its expansion across health and life sciences, as global biopharma company, Vertex Pharmaceuticals, confirms plans to build a new 155,000 sq. […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.